GSK delivers Q3 business performance*
EPS of 25.2p and increased dividend of 14p
Business performance results*
Q3 2008 Growth 9 months 2008
Growth
£m CER% £% £m CER% £%
Turnover 5,882 (3) 7 17,442 (2) 4
Earnings per share 25.2p (9) 6 78.0p (5) 4
Statutory results (including restructuring charges)
Q3 2008 Growth 9 months 2008
Growth
£m CER% £% £m CER% £%
Turnover 5,882 (3) 7 17,442 (2) 4
Earnings per share 20.1p (30) (15) 69.2p (16) (7)
The full results are presented under ‘Income Statement’ on pages 8 and 16.
Q3 business performance summary
• EPS down 9% at constant exchange rates, up 6% in sterling terms benefiting from
currency movements
• Continued sales growth in vaccines, emerging markets and consumer healthcare
helped offset impact of generic competition to US pharmaceuticals
• Portfolio renewal continues with 10 product launches so far in 2008, including
Rotarix (USA), Treximet (USA) and Tyverb (EU)
• Strong R&D productivity evident with a sustained level of around 30 assets in latestage
development
• Early progress in strategy to globalise and diversify business with ‘bolt-on’
acquisitions in emerging markets and consumer healthcare
• Q3 dividend increased 8% to 14p.
* Business performance, which is a supplemental measure, is the primary performance measure used by management and is presented after excluding restructuring charges relating to the current operational excellence
programme, which commenced in October 2007, and significant acquisitions. Management believes that exclusion of these items provides a better reflection of the way in which the business is managed and gives a more useful
indication of the underlying performance of the Group.
In order to illustrate underlying performance, it is the Group’s practice to discuss its results in terms of constant exchange rate (CER) growth. All commentaries are presented in terms of CER growth and compare 2008 business
performance results with 2007 statutory results, unless otherwise stated.

Chief Executive Officer’s Review
We are managing a considerable transition to our product portfolio this year as several mature pharmaceutical brands encounter generic competition in the USA. In the short-term, this is having a significant impact on pharmaceutical sales, although we continue to see good growth from other areas of the pharmaceuticals portfolio, including a recent improvement in
prescription volumes for Advair in the United States. Also helping offset the generic impact has been growth in other parts of our business, such as vaccines, emerging markets and consumer healthcare.
This diversification in sales is an inherent strength for GSK and one we are actively nurturing, through delivery and investment in our new strategic priorities. Ultimately, we are aiming to create a more balanced healthcare business with a lower overall risk profile.

More info on; http://www.gsk.com/investors/reports/q32008/q32008.pdf